Company: ZVRA
Filing Date: 2025-03-31
Form Type: PREC14A
Source: 0001193125-25-068746
Chunk: 30

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-03-31
Form: PREC14A
Chunk 30
---
 a director of our Company. Mr. Mangless has provided us with notice that he intends to nominate the Mangless Nominees for election as directors at the Annual Meeting. Although the Company is required to include the Mangless for election on its WHITEproxy card under universal proxy rules, for additional information regarding the Mangless Nominees and any other related information, please refer to Mr. Mangless’ proxy statement if and when it is provided to you by Mr. Mangless. You can access Mr. Mangless’ proxy statement, and any other relevant documents, without cost on the SEC’s website. The Board DOES NOTendorse the election of the Mangless Nominees. You may receive proxy solicitation materials from Mr. Mangless, including a proxy statement and blue proxy card.

| IF YOU DO RECEIVE SUCH PROXY MATERIALS FROM MR. MANGLESS, OUR BOARD STRONGLY URGES YOU TO DISCARD AND NOT TO SIGN OR RETURN MR. MANGLESS’S BLUE PROXY CARD OR TO VOTE FOR ANY OF THE MANGLESS NOMINEES. |

We believe that the director nominees proposed by our Board, with their breadth of relevant and diverse experience, are the most qualified candidates up for election at the Annual Meeting. Furthermore, our Board believes that the director nominees recommended and proposed by our Board would serve the interests of all of the Company’s stockholders better than the nominees proposed by one stockholder. If you have any questions or require any assistance with voting your shares, please contact Sodali & Co, our proxy solicitor assisting us in connection with the Annual Meeting: 430 Park Avenue, 14th Floor New York, New York 10022 Stockholders Call Toll-Free in North America: (800) 662-5200 Outside of North America Call Collect: (203) 658-9400 Email: ZVRA@info.sodali.com

| THE BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” EACH OF WENDY DIXON, PH.D. AND TAMARA A. FAVORITO USING THE ENCLOSED WHITE PROXY CARD. |

28

CLASS II DIRECTORS CONTINUING IN OFFICE UNTIL THE 2026 ANNUAL MEETING

John B. Bode

John B. Bode has served as a director of our Company since April 2023 and as chair of the Nominating and Corporate Governance Committee since May 2023. Since February 2015, Mr. Bode has